A Phase 2, Multicenter, Single-Arm, Open-Label Study to Determine the Efficacy and Safety of Single-Agent Lenalidomide (Revlimid (R)) in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Inclusion Criteria:

- Biopsy proven mantle cell lymphoma

- Patients must have documents relapsed, refractory or PD after treatment with
bortezomib

- Must have measureable disease on cross sectional imaging by CT

- Eastern Cooperative Oncology Group (ECOG) performance score 0,1 or 2

- Willing to follow pregnancy precautions

Exclusion Criteria:

- Any of the following laboratory abnormalities

- Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L)

- Platelet count < 60,000/mm3 (60 x 109/L)

- Serum aspartate transaminase/Serum glutamic oxaloacetic transaminase(AST/SGOT)
or alanine transaminase/Serum glutamic pyruvic transaminase (ALT/SGPT) > 3.0 x
upper limit of normal (ULN), except in patients with documented liver
involvement by lymphoma.

- Serum total bilirubin > 1.5 x ULN, except in cases of Gilbert's Syndrome and
documented liver involvement by lymphoma.

- Calculated creatinine clearance (Cockcroft-Gault formula) of < 30 mL /min

- Patients who are candidates for high dose chemotherapy/allogeneic stem cell
transplant are not eligible

- History of active central nervous system (CNS) lymphoma within the previous 3
months

- Subjects not willing or unable to take deep vein thrombosis (DVT) prophylaxis

- Prior history of malignancies, other than MCL, unless the patient has been free
of the disease for ≥ 3 years

- Positive Human immunodeficiency virus (HIV) or active Hepatitis B or C